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The papillomavirus E2 proteins function in viral transcriptional regulation, and genome replication and episomal maintenance. The
transactivation domain is essential for these activities. To identify functional regions, a structural model of the BPV1 E2 transactivation
domain was used to target surface residues for mutation. Mutation of several previously uncharacterized regions yielded proteins specifically
disrupted in the replication activity of E2. Mutations in an amino-terminal acidic amphipathic helix disrupted the interaction of the E1 and E2
proteins and a peptide derived from this helix blocked cooperative origin binding of E1 and E2. Mutation of clusters of charged residues,
R47, K48, K49, R58, and H61 or R172, D175, E176, and R179, or residue R68 in the previously described putative E1 interaction region,
specifically disrupted replication while retaining the ability to bind to the E1 protein. Thus, this approach has identified novel regions that are
required for the replication function of E2.
Published by Elsevier Inc.
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The papillomavirus transcriptional activator, E2, is
involved in key functions in the viral life cycle. In addition
to its role as the primary regulator of viral gene tran-
scription, E2 is essential for the efficient initiation of viral
DNA replication and is required for the segregation and
maintenance of viral genomes in dividing epithelial cells. In
addition to E2, papillomavirus DNA replication requires the
viral E1 protein and the origin of replication (Ustav and
Stenlund, 1991; Ustav et al., 1991). The viral origin of
replication comprises an E1 binding site and an AT-rich
region flanked by E2 DNA binding sites (Ustav et al.,
1991). The E2 protein participates in DNA replication by
binding cooperatively with the viral helicase, E1, to the viral0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2004.11.036
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E-mail address: amcbride@nih.gov (A.A. McBride).origin of replication (Blitz and Laimins, 1991; Mohr et al.,
1990; Seo et al., 1993). E2 has also been shown to interact
with the cellular replication protein A (Li and Botchan,
1993) and to alleviate nucleosomal repression of DNA
replication (Li and Botchan, 1994).
The cooperative binding of E2 and E1 to the origin is
mediated by an interaction between the transactivation
domain of E2 and the E1 protein (Winokur and McBride,
1996). Recently, our laboratory generated a new panel of
E2 proteins mutated in the transactivation domain (listed
in Table 1). In a new approach, groups of surface amino
acids were selected for mutation based on a structural
model of the BPV1 transactivation domain that was
derived by homology modeling using the crystal structure
of the HPV16 E2 transactivation domain (Antson et al.,
2000). A full characterization of the transcriptional
regulatory and mitotic chromosome binding properties
of this panel of mutations is described elsewhere (Baxter
et al., 2005). The aim of this study was to use this panel
of proteins to identify regions of the transactivation005) 78–88
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replication function of the protein. The analysis of the
replication phenotype of the mutated E2 proteins wasTable 1
Group E2
Protein
Mutationa Mitotic
chromosome
bindingb
Transcriptional
activationc
Amphipathic
helix
A1 E2A, E6A,
E13A, E20A
+++ +++
A2 E2Q, E6Q,
E13Q, E20Q
+++ +++
Charge cluster B1 D28N +++ ++
B2 D24N, K25Q,
D28N
+++ ++
B3 D24A, K25A,
D28A
 ts +/
Replication–E1 C1 R68A +++ +++
interaction C2 E39A +++ +++
C3 E39A, R68A +++ ++
C4 Q12A, Q15A,
E39A
+ ts +++
C5 Q12A, Q15A,
E39A, R68A
+ ts +
C6 R68Q +++ +++
C7 E39Q +++ +++
C8 E39Q, R68Q +++ ++
C9 Q12N, R68Q  ts +/
C10 Q12N, Q15N,
E39Q
 +/
C11 Q12N, Q15N,
E39Q, R68Q
 +/
Basic cluster D1 R47A, K48A,
K49A, R58A,
H61A
+++ +++
D2 R47Q, K48Q,
K49Q, R58Q,
H61N
++ +++
Transactivation F1 R37A ++ +++
self- F2 I73A + ++
interaction F3 R37A, I73A  +
F4 R37A, K70A,
E74A, Q76A,
Q80A
 +
F5 R37A, K70A,
I73A, E74A,
Q76A, Q80A
 +
F6 R37Q, K70Q,
E74Q, Q76A,
Q80A
 +/
Acidic cluster G1 D89A, E90A +++ +++
G2 E86A, D89A,
E90A
+++ +
G3 E86Q, D89N,
E90Q
+++ +++
Charge cluster H1 R172A, D175A,
E176A
++ +++
H2 R172A, D175A,
E176A, R179A
+++ +++
H3 R172Q, D175N,
E176Q, R179Q
+++ +++
Charge cluster I1 R189A, D190A,
D192A, R193A
 ts ++
I2 R189Q, D190N,
D192N, R193Q
 ts ++aided by the development of a real-time PCR-based
assay to measure replicated DNA.
Mutation of previously unidentified regions of the
transactivation domain resulted in a specific replication
defect. Mutation of one of these regions, an amino-terminal
amphipathic alpha-helix, was demonstrated to disrupt
interaction with the E1 protein, and peptide competition
experiments indicated that this alpha-helix is directly
involved in E2–E1 interaction.Results
We have recently generated a novel panel of BPV1 E2
proteins containing mutations in the amino-terminal trans-
activation domain in order to further map the various
functions and protein interactions of this key viral regulatory
protein (Baxter et al., 2005). Regions on the surface of the
domain likely to be involved in protein–protein interactions
were identified by homology modeling of the BPV1 E2
domain with the crystal structure of the HPV16 E2 domain
(Antson et al., 2000). Residues within the target regions
were either substituted conservatively or were changed to
alanines. A detailed description of the design and generation
of the panel of mutated E2 proteins is presented elsewhere,
as are the results of other functional assays related to the
transcriptional regulatory and viral genome segregation
functions of E2 (Baxter et al., 2005). Table 1 lists the
specific amino acids mutated in each protein along with a
summary of the activities of the proteins in mitotic
chromosome binding and transcriptional activation assays.
Fig. 1 shows the position of these residues on a model of the
BPV1 E2 transactivation domain.
Development of a real-time PCR-based analysis for the
transient DNA replication assay
To determine the ability of the mutated E2 proteins to
support papillomavirus replication, a transient replication
assay was carried out in which plasmids expressing the E1
and E2 proteins were cotransfected into CHO cells with a
replicon containing the BPVorigin of replication. Three to 4
days later, low molecular weight DNA was isolated and
assayed for replication by resistance to the DpnI restriction
enzyme, which can only cleave DNA that has been
methylated in bacteria.Notes to Table 1:
Data from (Baxter et al., 2005).
a Nomenclature is [original residue; position: substituted residue].
b Mitotic chromosome binding activity is expressed as the percentage of
mitotic cells with E2 bound to chromosomes; +++, N60%; ++, N30–60%; +,
N10–30% activity; +/, V10%. ts indicates temperature sensitive phenotype.
c Transcriptional activation is expressed as a percentage of wild type E2
activity. +++, N60% activity; ++, N30–60%; +, N10–30% activity; +/,
V10% activity.
Fig. 1. Structural model of BPV1 E2 transactivation domain. Shown are opposing views of a structural representation of the BPV1 E2 transactivation
domain. The model is displayed in spacefill mode with the eight mutation target groups (A–I) as indicated. Details of the mutations are published elsewhere
(Baxter et al., 2005). The locations of the amino (N) and carboxyl (C) termini of the transactivation domain are indicated in both views of the structural
model.
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replication was performed using a real-time PCR-based
assay as well as the more traditional Southern hybrid-
ization analysis. The real-time PCR-based assay also relies
on the resistance of DNA synthesized in eukaryotic cells to
digestion with DpnI. PCR primers AM724 and AM725
were designed to amplify a short sequence (nt 6876–7026
of the BPV-1 genome) that contains two DpnI sites, at nt
6948 and 6978 from the 3V end of the L1 open reading
frame (Fig. 2). The presence of two DpnI sites within the
amplicon increases the stringency of selection against
DpnI-sensitive, non-replicated plasmid because cleavage
at either site would render the plasmid unusable as a PCRFig. 2. Design of amplicon for real-time PCR assay of transient E2-dependent DNA
to 7946 and 1 to 83) contained within the plasmid replicon p716. The upper diagra
(long control region, ori). The upper diagram indicates the locations of the nine Dp
real-time PCR analysis of BPV DNA replication (nt 6876 to 7026) is shown below.
primers and the two DpnI sites located within the amplicon.template. Therefore, only replicated, and thus DpnI-
resistant, DNA would be able to act as a template for the
amplification of this sequence. In the real-time PCR assays,
the difference in the amount of replicated plasmid in
samples containing wild type E2 versus no E2 was almost
160-fold. Comparison of the data obtained by real-time
PCR analysis with those obtained by Southern indicated
that the two methods give very similar results (Fig. 3,
compare panels A, B, and C), validating the use of the
real-time PCR assay. Quantitative replication data pre-
sented for the panel of mutated E2 proteins is a
combination of results from both Southern blots and real-
time PCR assays (Fig. 4).replication. Two schematics of the BPV genomic DNA sequence (nt 4786
m shows the open reading frames (3Vend of L2, L1) and major cis elements
nI sites within this sequence (arrows). The detailed view of the amplicon for
Shown are the priming sites for the forward (AM724) and reverse (AM725)
Fig. 3. Comparison of data from parallel Southern hybridization and real-time PCR analyses of the same set of transient replication assays of the panel of
mutated E2 proteins. (A) Example of a Southern hybridization analysis, as described in Materials and Methods. (B and C) One set of low molecular weight
DNA preparations was digested with SalI and DpnI and analyzed either by agarose gel electrophoresis and Southern hybridization (B) or by real-time PCR (C),
as described in Materials and methods.
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amino and carboxyl termini of the transactivation domain
are required for function
The results from Southern and real-time PCR assays of
the transient DNA replication activity of the panel of
mutated E2 proteins were combined and are presented in
Fig. 4. Most mutations reduced replication activity
relative to that of the wild type E2 protein, with over
half of the panel having 10% or less activity. When the
replication effects of the various mutations were evaluated
in the context of effects on other E2 functions such as
mitotic chromosome binding, transcriptional activation,and transcriptional repression (Baxter et al., 2005), several
mutations were found to have more global impacts on E2
function. For example, replication-defective E2 proteins
C5, C10, C11, F4, F5, and F6 were also severely
defective in transcriptional activation and mitotic chro-
mosome binding (Table 1).
However, mutations in target groups A, D, and H
were found to have specific defects in the replication
function of E2. Amino acids in these groups, the amino-
terminal amphipathic alpha-helix (group A) and two
clusters of charged amino acids near the amino and
carboxy termini of the transactivation domain (groups D
and H) have not previously been linked to the replication
Fig. 4. DNA replication activity of mutated E2 proteins. Shown is a summary of results for the entire panel of mutated E2 proteins analyzed either by agarose
gel electrophoresis and Southern blot or by real-time PCR. Data represent the results of at least four separate analyses of three independent DNA preparations.
Activity is expressed relative to that of wild type E2, which has been set at 100%.
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tive mutations of residues in these target groups reduced
replication activity by about 90% or more (A1, 7.3%;
A2, 2.9%; D1, 8.0%; D2, 10.9%, H2, 8.1%; H3, 6.6%),
but all six proteins retained robust transcriptional
activation activity and were able to bind to mitotic
chromosomes.
Another notable result from the replication assay was
obtained for the E2 proteins with mutations in amino acid
39 (C2, E39A; C7, E39Q), a residue that has been
implicated by some studies in the replication function of
the E2 protein (Ferguson and Botchan, 1996; Sakai et al.,
1996). Proteins C2 (E39A) and C7 (E39Q) were found to
retain 52.0% and 54.3% of the wild type E2 replication
activity, respectively, indicating that in our assay system
the E39 residue does not play a major role in the
replication function of BPV E2. However, mutation of
another amino acid within the same putative replication–
E1 interaction target group, R68, did lead to a specific
loss of replication activity. Proteins C1 (R68A) and C6
(R68Q) retained only 12.2% and 6.9% of the wild type E2
replication activity, respectively, but were functional in
transcriptional regulation and mitotic chromosome binding
assays. The results for the R68 mutations provide evidence
that the putative replication surface does play a role in the
replication function of BPV1 E2, but that residue E39 is
not the key amino acid for this role in the BPV E2
protein.Cooperative origin binding studies demonstrate that the
first acidic amphipathic helix is important for interaction
with the E1 protein
E2 cooperatively binds to the papillomavirus origin of
replication with the E1 protein. E2 has also been shown to
interact with the cellular replication protein RPA (Li and
Botchan, 1993) and to alleviate nucleosome-mediated repres-
sion of BPV1 DNA replication (Li and Botchan, 1994). To
determine whether the replication defects observed for the
mutated E2 proteins were dependent on interaction with E1,
the ability of the panel of mutated E2 proteins to interact with
E1 and to participate in cooperative origin binding was
examined. In vitro-translated, 35S-labeled E2 (wild type or
mutated) and E1 proteins were mixed with three 32P-labeled
DNA fragments, one of which contains the BPV origin of
replication. The DNA–protein mixtures were then immuno-
precipitated with the E1-specific antibody SSQN, and
precipitated protein and DNAwere analyzed by SDS-PAGE.
As can be seen in the representative assay presented in Fig. 5,
panel A, addition of wild type E2 protein to the reaction
mixture dramatically increased the amount of E1 origin-
specific DNA binding (Fig. 5A, compare E1 alone and +WT
E2 samples). In the assay, E1 origin bindingwas enhanced 32-
fold bywild type E2. Results from three different experiments
were measured and averaged and are presented in Fig. 5B.
Only five mutated E2 proteins displayed cooperative
origin binding activities of less than 30% of the wild type
Fig. 5. Cooperative origin binding activity of mutated E2 proteins. Cooperative origin binding assays were carried out as described in Materials and methods.
Precipitated protein–DNA complexes were analyzed by SDS-PAGE on 10% acrylamide gels, followed by autoradiography and phosphorimaging on the fixed
and dried gel. (A) Shown is a representative image of the 32P signal from the SDS-PAGE gels. One ng 32P-labeled DNA probe was loaded as a marker (DNA).
The migration of the origin-containing fragment (ori), as well as those of the other 32P-labeled DNA fragments (*) is indicated on the left. E1 alone sample had
no E2 protein added to the reaction mixture. (B) Shown is the quantitation of cooperative origin binding results for the panel of mutated E2 proteins. Data
represent the results of three binding assays. Cooperative origin binding activity is expressed relative to that of wild type E2, which has been set at 100%.
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previously, proteins C5 (12.9% E1/origin binding activity),
C10 (6.1% E1/origin binding), and C11 (10.62% E1/origin
binding) have defects in all E2 functions measured, so the
results of the origin-binding assay are not informative.
However, since proteins A1 (26.2% E1/origin binding) and
A2 (20.1% E1/origin binding) exhibit a specific replication
defect, the reduction observed in cooperative origin binding
suggested that these mutations in the amino-terminal
amphipathic alpha-helix reduced the replication function
of the E2 protein by disrupting its interaction with E1.
The other mutated E2 proteins with specific replication
defects, C1 and C6 (in residue R68), D1 and D2 (N-terminal
basic cluster) and H2 and H3 (the C-terminal charge
cluster), retained 68.4%, 65.9%, 42.7%, 67.3%, 66.6%,
and 84.6% of wild type E2 cooperative origin binding
activity, respectively, indicating that these regions are not
critical for E1 interaction. However, one caveat with this
interpretation is that these proteins could be temperature
sensitive for E1 binding. The E1–E2 binding assay is carried
out at room temperature (23 8C) and it is possible that this
interaction would be disrupted in vivo at 37 8C. This could
also be true for the F4, F5 and F6 proteins. These proteins
are defective in all in vivo assays yet can cooperatively bindto the origin relatively efficiently. This could indicate that
these mutations have slightly disrupted conformation, in
addition to more specific defects. Reduction in temperature
and/or interaction with E1 could induce the E2 protein to
fold more correctly. Another explanation for the relatively
high E1–E2 binding activities observed in vitro could be
due to differences in the concentrations of E1, E2, and
origin DNA in these assays relative to the transient
replication assays.
Peptide competition studies demonstrate that the
amphipathic alpha-helix is involved in direct interaction
with E1
The apparent disruption of E1 binding by mutation of the
acidic residues in the amphipathic alpha-helix indicated that
this region was involved in the E1–E2 interaction. This was
tested more directly by competition of the E1-binding
activity of wild type E2 protein, as measured in the
cooperative origin binding assay, with a peptide that spans
amino acids 1–24 of E2 (META). This peptide contains all
of the amino acids that were mutated in the A1 and A2
proteins (E2, E6, E13, and E20) and constitutes the first
alpha helix in the N-terminus of the E2 protein. When this
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E2 binding reaction, the amount of origin fragment
immunoprecipitated with the anti-E1 antibody SSQN
decreased dramatically (Fig. 6, compare lane 3 to lane 2).
Quantitation of the 35S-labeled E1 bands in the immuno-
precipitates found that the META peptide also reduced the
amount of E1 protein in the complex (data not shown).
However, when this decrease was factored into the origin
binding quantitation, the META peptide was still found to
diminish cooperative origin binding by approximately 80%.
A corresponding peptide with alanine substitutions in E2,
E6, E13, and E20 was synthesized to use as a negative
control, but was found to be insoluble. Therefore, another
peptide, representing amino acids 66–90 of the BPV E2
protein, was used and was found to have no effect on
cooperative origin binding when tested at the same
concentration (200 AM) as the META peptide (data not
shown). Two different anti-E2 antibodies, B201 and B202,
were used to corroborate the results with SSQN, since
cooperative E2–E1 binding to the origin can also be assayed
by immunoprecipitation of E1–E2 protein–DNA complexes
by the E2 protein. Greatly enhanced binding of E2 to the
origin fragment was observed upon addition of E1 (Fig. 6,Fig. 6. Peptide competition of cooperative origin binding. The effect of a
peptide representing the amino-terminal 24 amino acids of the BPV1 E2
protein on cooperative origin binding was tested. Shown here is an image of
the SDS-PAGE gel. Three different antibodies were used to immunopre-
cipitate protein–DNA complexes: the anti-E1 rabbit polyclonal antibody
SSQN (lanes 1–3), the anti-E2 monoclonal antibody B202 (lanes 4–6), and
the anti-E2 monoclonal antibody B201 (lanes 7–9). Lanes 1, 4, and 7
contained target antigen (either E1 or E2) plus DNA. Lanes 2, 5, and 8
contained E1, E2, and DNA. Lanes 3, 6, and 9 contained E1, E2, DNA, and
the peptide (META). Peptide was added to binding reactions at a
concentration of 200 AM. One ng of 32P-labeled DNA probe was loaded
as a marker (DNA). The migration of the origin-containing fragment (ori),
as well as those of the other 32P-labeled DNA fragments (*), is indicated on
the left.compare lanes 5 and 8 to lanes 4 and 7, respectively) to the
binding reactions. This enhancement was eliminated when
the META peptide was included in the reaction mixtures
(Fig. 6, lanes 6 and 9), confirming that the peptide can block
the cooperative binding of E1 and E2 to the origin of
replication by interfering with E2–E1 interaction.Discussion
The papillomavirus E2 protein serves several important
functions in the viral life cycle, including initiation of viral
DNA replication, positive and negative regulation of viral
gene transcription, and viral genome segregation and
episomal maintenance. These functions all require the N-
terminal transactivation domain of E2. Previous mutational
studies of the transactivation domain have indicated that the
domain is very sensitive to perturbation and must maintain
its structural integrity to function. For example, deletion
mutations within the domain were found to disrupt both
transcriptional activation and replication activities of E2
(McBride et al., 1989b; Winokur and McBride, 1992).
Several point mutations of conserved amino acids within
this domain have also been shown to nonspecifically disrupt
domain-dependent functions (Abroi et al., 1996; Brokaw et
al., 1996), apparently by disrupting the structure of the
domain (Zheng et al., in press). This sensitivity to mutation
has made it difficult to definitively identify the regions
within the transactivation domain that are involved in
specific E2 functions. The crystal structure of the HPV16
transactivation domain revealed that the domain is highly
ordered, with extensive alpha-helical and beta sheet
organization (Antson et al., 2000). In an effort to better
delineate the functionally important surface residues within
the domain, a new mutational analysis was undertaken
targeting groups of amino acids identified from a structural
model of the BPV1 E2 transactivation domain (Table 1).
The study presented here focused on the characteristics of
the panel of mutated E2 proteins with respect to the
replication function of E2.
To that end, a real-time PCR-based assay of the
replication of a BPV1 origin-containing plasmid replicon
was developed. A short PCR amplicon containing two DpnI
restriction sites was designed to discriminate between
unreplicated input DNA and DpnI-resistant replicated
DNA. The real-time PCR assay allowed at least two orders
of magnitude discrimination between samples with or
without E2. When the PCR-based assay was directly
compared to the Southern-based assay for evaluation of
the panel of mutated E2 proteins, the results were quite
similar (Fig. 3), indicating that the real-time PCR assay is an
appropriate alternative to the traditional replication assay.
Other studies have also incorporated a PCR step: Sakai and
colleagues amplified a sequence from an HPV16 origin-
containing replicon for ten cycles of endpoint PCR to
improve the sensitivity of their replication assay (Sakai et
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development of a real-time PCR-based replication assay for
HPV16 replicons (Taylor and Morgan, 2003; Wang et al.,
2003). However, Taylor and Morgan had to engineer DpnI
cleavage sites into the replicon used in their experiments
whereas in this study we used naturally occurring sites in the
viral genome. In addition, the latter two groups used
Taqman probes to measure the amplified PCR products.
We find that the less expensive SYBR Green detection is
sufficient for this assay.
The measurement of the replication activities of the
mutated E2 proteins demonstrated that although several
proteins exhibited reduced replication function (Fig. 4), only
a handful of defective proteins remained active in other
assays of E2 function (Baxter et al., 2005). Mutations in
target groups A, D, and H gave rise to proteins that were
specifically defective in the replication function of E2,
possessing replication activities of about 10% or less than
that of the wild type E2 protein. Amino acids that were
mutated within groups A (E2, E6, E13, E20), D (R47, K48,
K49, R58, H61) or H (R172, D175, E176, R179) have not
previously been associated with the replication function of
E2.
The panel of mutated E2 proteins was assayed for the
ability to interact with the E1 protein and cooperatively bind
to the BPV1 origin of replication. This was done to
determine whether the replication defects observed among
the mutated proteins were E1-dependent or E1-independent.
Overall, most of the mutated E2 proteins in the panel retained
cooperative origin binding activities at greater than 50% of
the wild type E2 level. Among the mutations that had
specific replication defects, only mutations of the amino-
terminal amphipathic alpha-helix demonstrated a consider-
able defect in cooperative origin binding. These findings
indicate that the amphipathic helix is directly involved in
binding to the E1 protein and suggest that residues in the
other replication defective groups are inactive for reasons
other than E1 binding. The exact nature of the role of these
clusters of charged amino acids remains to be determined.
The ability of a peptide comprising the amino-terminal 24
amino acids of BPV1 E2 to inhibit the cooperative binding
of E2 and E1 to the viral origin of replication (Fig. 6)
supports the proposed involvement of the amphipathic
alpha-helix in direct interaction with E1. However, the
relatively high concentration of peptide that was required for
inhibition of binding, taken together with the incomplete
reduction in cooperative origin binding upon mutation of the
acidic residues within the amphipathic helix, suggests that
there are additional regions on the surface of the trans-
activation domain of E2 that may make contact with E1.
Peptide competition experiments with the HPV16 E2
protein, using a peptide that included E39, confirmed that
this region was also important for the interaction of HPV16
E2 with the HPV16 E1 protein (Kasukawa et al., 1998).
Mutation of R68 in target group C also led to a specific
loss of replication function. The reason that target group Cwas selected for investigation was that another amino acid
in this group, E39, had been implicated from previous
mutational studies as a key residue for the replication
activity of various E2 proteins and for E2–E1 interaction
(Brokaw et al., 1996; Cooper et al., 1998; Ferguson and
Botchan, 1996; Sakai et al., 1996). In addition, each of these
residues has been shown to directly contact the E1 protein in
an X-ray crystal structure of the HPV18 E1 and E2 proteins
(Abbate et al., 2004). In this study, mutation of E39 to
alanine or glutamine (C2 and C7) alone had a minimal effect
on the replication activity of the BPV1 E2 protein. These
results are in agreement with those of Abroi and colleagues,
who observed no replication defect in BPV1 E2 with an
E39A mutation (Abroi et al., 1996), as well as with a recent
report on a codon-optimized HPV16 E2, where the E2
protein with mutation E39A retained around 50% of the
wild type E2 activity (Wang et al., 2003). Mutation of amino
acid E39 (or R68) had little effect on cooperative origin
binding (Fig 5B, samples C2 and C7), and by extension, E1
interaction. This is in contrast to what has been found for the
HPV16 E2 protein, which requires E39 for interaction with
E1(Sakai et al., 1996). However, one consideration is that
certain amino acid substitutions could result in temperature-
sensitive proteins that are able to bind E1 in the room
temperature (23 8C) binding assay but are unable to support
replication in vivo. In fact, Ferguson and Botchan have
demonstrated that the BPV1 R68A protein is temperature
sensitive for replication (Ferguson and Botchan, 1996) and
we have previously found that a different substitution in
residue 39, E39D, also results in a temperature-sensitive
replication phenotype (Zheng et al., in press). This could
also be the case for the F4, F5, and F6 proteins described
above.
Notably, in the crystal structure of the HPV16 E2
transactivation domain residues E39 and R68 are oriented
in the same direction and are in very close proximity
(Antson et al., 2000). The different phenotypes of E39 and
R/K68 mutations among different papillomavirus E2 pro-
teins suggest that the nature of the interaction between the
BPV E1 and E2 proteins may be somewhat different than
the interaction between the HPV16 proteins. Abbate and
Botchan recently solved the crystal structure of the HPV18
E2 transactivation domain in complex with a C-terminal
portion (residues 428–631) of the E1 protein (Abbate et al.,
2004). In support of our data, they find that the N-terminal
three-helical bundle of the E2 transactivation domain is
important for interaction with E1, and that the C-terminal h-
sheet region is not involved in this interaction. In the
structure, the C-terminal part of the first acidic amphipathic
helix (residues 12 to 22 in the homologous BPV1 E2
protein) makes the most extensive contacts with the E1
protein. Furthermore, Abbate et al. find that in the HPV18
E2 protein the E39 residue makes critical contacts with a
residue in the E1 protein that is not conserved in BPV1. This
could explain why different phenotypes are observed in E39
mutations among different papillomavirus E2 proteins.
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K49, R58, H61) are located between the second and third
alpha helices of the transactivation domain. In the HPV18
E1 and E2 structure solved by Abbate et al., the residue
equivalent to BPV1 E2 58 (and surrounding residues) made
contact with the E1 protein. Residues 58 and 61 are not
conserved between HPV18 and BPV1 proteins but never-
theless non-conserved residues at equivalent positions may
be important for the interaction between the E1 and E2
proteins. In our study, mutation of these residues reduced
but did not eliminate E1 binding; this could explain, at least
in part, the replication defect of the D1 and D2 proteins.
In summary, we have identified several previously
unrecognized regions of the BPV1 E2 transactivation
domain that are important for its replication function and
have provided further insight into the previously identified
E1 interaction region (region C). We further demonstrate
that region A, the amino-terminal amphipathic alpha-helix,
is involved in direct interaction with the E1 protein. These
regions are shown on the model of the transactivation
domain in Fig. 7.Materials and methods
Plasmids
The parent plasmid for generation of site-specific
mutations in the E2 transactivation domain, pTZE2kz, hasFig. 7. Location of key mutations on the transactivation domain. The
position of mutations that are involved in the replication function of E2 are
shown on a model of the BPV1 E2 transactivation domain.been described previously (McBride et al., 1989a) and a
detailed description of the generation of the panel of
mutated E2 proteins is described elsewhere (Baxter et al.,
2005). This series of pTZE2kz-based plasmids was used for
in vitro expression of mutated E2 proteins. To generate
vectors for expression in mammalian cells, the mutated E2
genes were excised from the pTZE2 constructs by HindIII/
BamHI digestion and were subcloned into the inducible
episomal expression vector pMEP-4 (Invitrogen). The
plasmid replicon p716 contains a fragment of the BPV-1
genome (nt 4786–7946 and 1–83) cloned into pTZ18R
(Winokur and McBride, 1992). The BPV-1 E1 expression
plasmid, pCG E1Eag 1235, has been described (Ustav and
Stenlund, 1991). Plasmid p1126 was used for in vitro
expression of E1 and has also been described previously
(Sarafi and McBride, 1995).
Transient DNA replication assay
CHO cells (5  106 cells at a density of 2  107 cells/ml)
were electroporated with 5 Ag of pMEP-E2 expression
plasmid, 5 Ag of pCG E1Eag 1235 (Ustav and Stenlund,
1991), and 2 Ag of p716 replicon plasmid. Three to 4 days
later, low molecular weight DNAwas isolated by a modified
Hirt extraction procedure (Ustav and Stenlund, 1991). For
Southern blot analysis, the isolated DNA was digested with
SalI (to linearize) and DpnI (to degrade any input plasmid),
and then analyzed by agarose gel electrophoresis followed
by Southern hybridization. A PCR-generated probe was
synthesized from the Long Control Region (LCR) (nt 6857–
7946 and 1–36), 32P-labeled by the random priming method
and used in Southern hybridizations.
Real-time PCR assay of DNA replication
Real-time PCR assay of DNA replication was based on
the resistance of DNA synthesized in eukaryotic cells to
digestion by the methylation-dependent restriction enzyme
DpnI. Primers for real-time PCR (AM724 and AM725)
were designed to amplify an amplicon spanning nucleotides
6876–7026 of the BPV genome, which contains two DpnI
sites (Fig. 2). Forward primer AM724 (BPV nt 6876–6902)
has the sequence 5V-CAACTAAATGTGCAAGCAATG-
TAATTC-3V. Reverse primer AM725 (BPV nt 7026–7009)
has the sequence 5V-CATCCTGCCCCTTGCTGT-3V. Low
molecular weight DNA was harvested as for the traditional
analysis by Southern hybridization and was digested with
DpnI. In some cases, the same digested DNA was used for
both Southern analysis and real-time PCR analysis. In these
cases, the DNA was digested with both SalI and DpnI.
Real-time PCR reactions were carried out using the
SYBR Green PCR Master Mix (ABI). Digested Hirt extracts
were diluted 1:100 prior to use in the PCR reactions. A
standard curve was generated with serial 10-fold dilutions of
undigested replicon plasmid (from 10 pg to 0.01 fg) for a
quantitative comparison of the DNA from the Hirt extracts.
M.K. Baxter, A.A. McBride / Virology 332 (2005) 78–88 87PCR was performed on the ABI Prism 7900HT Sequence
Detection System platform. Data were analyzed using
Sequence Detection Software version 2.1 (ABI).
Protein extracts and antibodies
35S-labeled proteins were expressed from the in vitro
expression plasmids described above using the TNT T7
Quick coupled reticulocyte lysate system (Promega). An
aliquot of each reaction was analyzed by SDS-polyacryla-
mide gel electrophoresis and the radiolabeled proteins were
quantitated using a Typhoon phosphorimager with Image-
Quant software (Molecular Dynamics). The E1-specific
rabbit antiserum, SSQN, has been described previously
(Spalholz et al., 1993). Anti-E2 monoclonal antibodies
B201 and B202 were provided by Elliot Androphy.
Cooperative origin binding assay
E1–E2 cooperative origin binding was measured using a
DNA–protein co-immunoprecipitation assay. The plasmid
KS+ ori contains BPV-1 nt 7781 to 7946 and 1 to 83 cloned
into the BamHI and HindIII sites of pBluescript KS+
(Spalholz et al., 1993). Plasmid KS+ ori was cleaved with
BamHI, HindIII, and AflIII, releasing a 250-bp origin-
containing fragment and a 400-bp fragment from the vector
that was used as a control for nonspecific DNA binding. The
digested DNA fragments were end-labeled with alpha-[32P]-
dCTP using the Klenow fragment of DNA polymerase I.
For the binding reaction, equivalent amounts of in vitro-
translated E2 protein (normalized to wild type E2) were
mixed with a limiting quantity of in vitro-translated E1
protein in a solution containing 10 Ag sonicated salmon
sperm DNA, a binding buffer (20 mM HEPES, pH 7.4, 5
mM magnesium acetate, 0.2 mM EDTA, 1 mM DTT), and
a volume of Buffer C-300 (20 mM HEPES, pH 7.9, 25%
(v/v) glycerol, 300 mM NaCl, 1.5 mM MgCl2) to adjust the
final salt concentration (upon addition of 32P-labeled DNA
probe) to 150 mM. Insoluble protein was removed by
centrifugation, and 200 ng of DNA probe was added,
bringing the reaction volume to 100 Al. After 2 h of
incubation at 23 8C, protein A-Sepharose beads containing
prebound affinity-purified antiserum SSQN were added to
the binding reaction mixture, which was mixed at 23 8C for
1 h. Immune complexes were washed three times in NET-
100 (50 mM HEPES, pH 7.4, 100 mM NaCl, 5 mM EDTA,
10 mM DTT, 0.1% Triton X-100). Beads were suspended
in 60 Al of 1 SDS-PAGE sample loading buffer, and half
of the sample was analyzed by SDS-PAGE and autoradio-
graphy and phosphorimaging. To obtain 32P-labeled DNA
signal only, a piece of X-ray film was used to block the
35S-labeled protein signal from reaching the film or
phosphorimage screen. Bands on phosphorimages were
quantitated using ImageQuant software, and values were
normalized to the amount of E1 protein in each loaded
sample.Peptide competition
A peptide comprising the 24 amino-terminal amino
acids of the BPV1 E2 protein (METACERLHVA-
QETQMQLIEKSSD) was synthesized and used in com-
petition experiments. Peptide was added, at a final
concentration of 200 AM, along with DNA probe to coo-
perative origin binding reactions after removal of insoluble
proteins. Binding reactions were then carried out as
described above, except that the antibodies used in the
immunoprecipitations were directed against either the E1
protein (SSQN) or the E2 protein (B202, B201). For the anti-
E2 immunoprecipitations, values for origin binding were
normalized to the amount of E2 protein in each loaded
sample.
A peptide representing amino acids 66–90 of the BPV1
E2 protein was also synthesized and used as a control
peptide at a concentration of 200 AM.Acknowledgments
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